Comparison · NCT01940900-sae
E10030 + Ranibizumab vs Sham + Ranibizumab: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. E10030 + Ranibizumab vs Sham + Ranibizumab: serious adverse events. Trial comparisons, record NCT01940900-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01940900-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.179 | 0.141 | 0.226 | wilson | |
| Risk in group 2 | 0.156 | 0.12 | 0.2 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0234 | -0.0353 | 0.0821 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.15 | 0.811 | 1.63 | log | |
| Odds ratio, group 1 over group 2 | 1.18 | 0.777 | 1.8 | log | |
| Number needed to harm, for one more participant with a serious adverse event on E10030 + Ranibizumab than on Sham + Ranibizumab | 42.7 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | E10030 + Ranibizumab | E10030 1.5 mg intravitreal injection + ranibizumab 0.5 mg intravitreal injection~E10030~ranibizumab | 56 | 312 | EG000 |
| Group 2 | Sham + Ranibizumab | E10030 sham intravitreal injection + ranibizumab 0.5 mg intravitreal injection~ranibizumab~E10030 sham intravitreal injection: Pressure on the eye with a syringe with no needle | 49 | 314 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Up to 12 months of exposure
Source ClinicalTrials.gov
Trial
- Title
- A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy
- NCT number
- NCT01940900
- Phases
- PHASE3
- Conditions
- Age-Related Macular Degeneration
- Interventions
- E10030, ranibizumab, E10030 sham intravitreal injection
- Lead sponsor
- Ophthotech Corporation
- Results first posted
- 2018-08-15
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01940900?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01940900-sae